Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue

• Published in: Diagnostic pathology 2022-11, Vol.17 (1), p.1-88, Article 88
• Main Authors: Sugita, Shintaro, Takenami, Tomoko, Kido, Tomomi, Aoyama, Tomoyuki, Hosaka, Michiko, Segawa, Keiko, Sugawara, Taro, Fujita, Hiromi, Shimizu, Junya, Murahashi, Yasutaka, Emori, Makoto, Hasegawa, Tadashi
• Format: Article
• Language: English
• Subjects: Aneurysm; Antibodies; Bone tumors; Cell differentiation; Cloning; Collagen; Colony-stimulating factor; CSF1; Cysts; Diagnosis; Diffuse type; Fluorescence; Fluorescence in situ hybridization; Fusion protein; Gene expression; Granulomas; Histology; Hybridization; Immunohistochemistry; Lesions; Localized type; Macrophage colony-stimulating factor; mRNA; Proteins; RNA; Sarcoma; Sheaths; Soft tissues; Synovium; Tenosynovial giant cell tumor; Translocation; Tumor cells; Tumors; Viral antibodies
• ISSN: 1746-1596; 1746-1596
• DOI: 10.1186/s13000-022-01266-9

Background Tenosynovial giant cell tumor (TSGCT) is a benign fibrohistiocytic tumor that affects the synovium of joints, bursa, and tendon sheaths and is categorized into localized TSGCT (LTSGCT) and diffuse TSGCT (DTSGCT). LTSGCT and DTSGCT are characterized by recurrent fusions involving the colony-stimulating factor 1 (CSF1) gene and its translocation partner collagen type VI alpha 3 chain. The fusion gene induces intratumoral overexpression of CSF1 mRNA and CSF1 protein. CSF1 expression is a characteristic finding of TSGCT and detection of CSF1 mRNA and CSF1 protein may be useful for the pathological diagnosis. Although there have been no effective anti-CSF1 antibodies to date, in situ hybridization (ISH) for CSF1 mRNA has been performed to detect CSF1 expression in TSGCT. We performed CSF1 immunohistochemistry (IHC) using anti-CSF1 antibody (clone 2D10) in cases of TSGCT, giant cell-rich tumor (GCRT), and GCRT-like lesion and verified its utility for the pathological diagnosis of TSGCT. Methods We performed CSF1 IHC in 110 cases including 44 LTSGCTs, 20 DTSGCTs, 1 malignant TSGCT (MTSGCT), 10 giant cell tumors of bone, 2 giant cell reparative granulomas, 3 aneurysmal bone cysts, 10 undifferentiated pleomorphic sarcomas, 10 leiomyosarcomas, and 10 myxofibrosarcomas. We performed fluorescence ISH (FISH) for CSF1 rearrangement to confirm CSF1 expression on IHC in TSGCTs. We considered the specimens to have CSF1 rearrangement if a split signal was observed in greater than 2% of the tumor cells. Results Overall, 50 of 65 TSGCT cases, including 35 of the 44 LTSGCTs and 15 of the 20 DTSGCTs, showed distinct scattered expression of CSF1 in the majority of mononuclear tumor cells. MTSGCT showed no CSF1 expression. Non-TSGCT cases were negative for CSF1. FISH revealed CSF1 rearrangement in 6 of 7 CSF1-positive cases on IHC. On the other hand, FISH detected no CSF1 rearrangement in all CSF1-negative cases on IHC. Thus, the results of IHC corresponded to those of FISH. Conclusion We revealed characteristic CSF1 expression on IHC in cases of TSGCT, whereas the cases of non-TSGCT exhibited no CSF1 expression. CSF1 IHC may be useful for differentiating TSGCTs from histologically mimicking GCRTs and GCRT-like lesions. Keywords: Tenosynovial giant cell tumor, Localized type, Diffuse type, CSF1, Immunohistochemistry, Fluorescence in situ hybridization